Peliminary experience of transcatheter aortic valve implantation with VENUS-Avalve
10.3969/j.issn.1004-8812.2017.09.003
- VernacularTitle:应用VENUS-A瓣膜行经导管主动脉瓣置入术的初步经验
- Author:
Jie LI
1
;
fang Jian LUO
;
xin Rui FAN
;
yu Huan DING
;
Guang LI
;
jiang Chang YU
;
Ming FU
;
bin Cheng ZHOU
;
yan Ji CHEN
;
Jian ZHUANG
Author Information
1. 广东省心血管病研究所血管病诊疗中心 广东省人民医院 广东省医学科学院
- Keywords:
Aortic stenosis;
Transcatheter aortic valve implantation;
VENUS-A valve
- From:
Chinese Journal of Interventional Cardiology
2017;25(9):486-490
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the experience of transcatheter aortic valve implantation (TAVI) in the treatment of severe aortic stenosis (AS) with VENUS-A valve. Methods Retrospectively collected and analyzed the baseline characteristics,preoperative assessment, surgery details,early and mid-term clinical outcome of 10 patients who underwent TAVI. Results From April 2016 to April 2017,10 patients with severe AS were treated with TAVI at the Guangdong General Hospital. The median age was 75 (65,81)years old and 5(5/10)were males. The median Society of Thoracic Surgery score was 5% (2%,11%). TAVI was successful in 10 patients (10/10),and percutaneous coronary intervention was performed in two cases (2/10) at the same time. The median operation time was 190 (150,225) minutes,the ICU monitoring time was 113 (49, 231) hours,and the hospital stay was 12 (6,25) days. After the procedure,the mean aortic-valve gradient reduced to 10(6,21)mmHg(1 mmHg=0.133 kPa). There was minimal or mild marginal periprosthetic leak in five patients(5/10)and moderate leak in one patient(1/10). During the 30 days of follow up,one patient(1/10)die due to perioperative myocardial infarction and ventricular fibrillation. One patient(1/10)was implanted with a permanent pacemaker for severe arrhythmia. Two patients(2/10)occurred vascular complications. The median follow-up was 3(1,15)months. One patient had syncope at 6 months post operation with R-R interval up to 7 seconds and he was implanted with a permanent pacemaker. There was no death,stroke,surgical surgery intervention and rehospitallization due to heart failure during the follow up. Conclusions It is feasible,safe and effective to use VENUS-A valve for TAVI treatment in serve AS.
